Utility of maximum inspiratory and expiratory pressures as a screening method for respiratory insufficiency in slowly progressive neuromuscular disorders


      • MIP and MEP can serve as a screening parameter for patients with neuromuscular disorders.
      • Parallel testing of both MIP and MEP needs to be performed to increase the positive prediction probability across disease groups.
      • Predicted values of MIP and MEP should be calculated for a more comprehensive interpretation of manometry results.
      • Disease-specific cut-offs of MIP and MEP did not increase the prediction rate of patients with abnormal FVC and FEV1.


      The aim of this study was to assess whether different cut-offs of maximum inspiratory and/or expiratory pressure (MIP/MEP) are valuable screening parameters to detect restrictive respiratory insufficiency. Spirometry, MIP, MEP and capillary blood gas analysis were obtained from patients with confirmed neuromuscular disorders. We calculated regression analysis, sensitivity, specificity and predictive values. We enrolled 29 patients with myotonic dystrophy type 1 (DM1), 19 with late-onset Pompe disease (LOPD), and 24 with spinal muscular atrophy type 3. Moderate to high reduction in manometry was exclusively found in LOPD and DM1 patients. Significant associations were found between manometry and spirometry. Highest adjusted r2 was found for MIP % predicted and forced vital capacity (FVC) % predicted. Manometry predicted abnormal FVC and forced expiratory volume 1 s (FEV1). MEP > 80 cmH2O predicted normal FVC and FEV1, regardless of cut-off values. MIP and MEP did not positively predict alterations in capillary blood gas analysis. Disease-specific cut-offs of manometry did not increase the prediction rate of patients with abnormal FVC and FEV1. Predicted values should be calculated for a more comprehensive interpretation of manometry results. MIP and MEP can serve as a screening parameter for patients with neuromuscular disorders, but parallel testing of both MIP and MEP needs to be performed to increase the positive prediction probability across disease groups.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Neuromuscular Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sachs M.C.
        • Enright P.L.
        • Hinckley Stukovsky K.D.
        • Jiang R.
        • Barr R.G.
        • Multi-Ethnic Study of Atherosclerosis Lung S.
        Performance of maximum inspiratory pressure tests and maximum inspiratory pressure reference equations for 4 race/ethnic groups.
        Respir Care. 2009; 54: 1321-1328
        • Cho H.E.
        • Lee J.W.
        • Kang S.W.
        • Choi W.A.
        • Oh H.
        • Lee K.C
        Comparison of pulmonary functions at onset of ventilatory insufficiency in patients with amyotrophic lateral sclerosis, duchenne muscular dystrophy, and myotonic muscular dystrophy.
        Ann Rehabil Med. 2016; 40: 74-80
        • Lyall R.A.
        • Donaldson N.
        • Polkey M.I.
        • Leigh P.N.
        • Moxham J
        Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis.
        Brain. 2001; 124: 2000-2013
        • Boentert M.
        • Wenninger S.
        • Sansone V.A
        Respiratory involvement in neuromuscular disorders.
        Curr Opin Neurol. 2017; 30: 529-537
        • Winkel L.P.
        • Hagemans M.L.
        • van Doorn P.A.
        • et al.
        The natural course of non-classic Pompe's disease; a review of 225 published cases.
        J Neurol. 2005; 252: 875-884
        • Heatwole C.
        • Bode R.
        • Johnson N.
        • et al.
        Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).
        Neurology. 2012; 79: 348-357
        • Mathieu J.
        • Allard P.
        • Potvin L.
        • Prevost C.
        • Begin P
        A 10-year study of mortality in a cohort of patients with myotonic dystrophy.
        Neurology. 1999; 52: 1658-1662
        • American Thoracic Society/European Respiratory S
        ATS/ERS Statement on respiratory muscle testing.
        Am J Respir Crit Care Med. 2002; 166: 518-624
        • Evans J.A.
        • Whitelaw W.A.
        The assessment of maximal respiratory mouth pressures in adults.
        Respir Care. 2009; 54: 1348-1359
        • De Troyer A.
        • Borenstein S.
        • Cordier R
        Analysis of lung volume restriction in patients with respiratory muscle weakness.
        Thorax. 1980; 35: 603-610
        • Tilanus T.B.M.
        • Groothuis J.T.
        • TenBroek-Pastoor J.M.C.
        • et al.
        The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis.
        Respir Res. 2017; 18: 144
        • Van der Beek N.A.
        • Hagemans M.L.
        • Reuser A.J.
        • et al.
        Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
        Neuromusc Disord NMD. 2009; 19: 113-117
        • van der Beek N.A.
        • van Capelle C.I.
        • van der Velden-van Etten K.I.
        • et al.
        Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.
        Mol Genet Metab. 2011; 104: 129-136
        • Schoser B.
        • Fong E.
        • Geberhiwot T.
        • et al.
        Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature.
        Orphanet J Rare Dis. 2017; 12: 52
        • Johnson E.M.
        • Roberts M.
        • Mozaffar T.
        • Young P.
        • Quartel A.
        • Berger K.I
        Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease.
        Neuromuscul Disord. 2016; 26: 136-145
        • Sansone V.A.
        • Gagnon C.
        participants of the 207th EW. 207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27-29 June 2014.
        Neuromuscul Disord. 2015; 25 (Naarden, The Netherlands): 432-442
        • Wallgren-Pettersson C.
        • Bushby K.
        • Mellies U.
        • Simonds A.
        Enmc. 117th ENMC workshop: ventilatory support in congenital neuromuscular disorders – congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003.
        Neuromuscul Disord. 2004; 14 (Naarden, The Netherlands): 56-69
        • Windisch W.
        • Walterspacher S.
        • Siemon K.
        • Geiseler J.
        • Sitter H.
        German Society for P. Guidelines for non-invasive and invasive mechanical ventilation for treatment of chronic respiratory failure. Published by the German Society for Pneumology (DGP).
        Pneumologie. 2010; 64: 640-652
        • Sharma G.D.
        Pulmonary function testing in neuromuscular disorders.
        Pediatrics. 2009; 123: S219-S221
      1. Landsberg J. Pulmonary function testing. 2018: 22–35.

        • Black L.F.
        • Hyatt R.E
        Maximal respiratory pressures: normal values and relationship to age and sex.
        Am Rev Respir Dis. 1969; 99: 696-702
        • Leech J.A.
        • Ghezzo H.
        • Stevens D.
        • Becklake M.R
        Respiratory pressures and function in young adults.
        Am Rev Respir Dis. 1983; 128: 17-23
        • Wilson S.H.
        • Cooke N.T.
        • Edwards R.H.
        • Spiro S.G
        Predicted normal values for maximal respiratory pressures in caucasian adults and children.
        Thorax. 1984; 39: 535-538
        • Tudorache V.
        • Oancea C.
        • Mladinescu O.F
        Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation.
        Int J Chron Obstruct Pulmon Dis. 2010; 5: 119-123
        • Rochester D.F.
        • Braun N.M.
        Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease.
        Am Rev Respir Dis. 1985; 132: 42-47
        • Babacic H.
        • Goldina O.
        • Stahl K.
        • et al.
        How to interpret abnormal findings of spirometry and manometry in myotonic dystrophies?.
        J Neuromuscul Dis. 2018; 5: 451-459
        • Pechmann A.
        • Konig K.
        • Bernert G.
        • et al.
        SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.
        Orphanet J Rare Dis. 2019; 14: 18
        • Criée C.
        • Baur X.
        • Berdel D.
        • Bösch D
        Leitlinie zur spirometrie leitlinie der deutschen atemwegsliga, der deutschen gesellschaft für pneumologie und beatmungsmedizin und der deutschen gesellschaft für arbeitsmedizin und umweltmedizin zur spirometrie.
        Pneumologie. 2015; 69: 147-164
        • Fuller D.D.
        • ElMallah M.K.
        • Smith B.K.
        • et al.
        The respiratory neuromuscular system in Pompe disease.
        Respir Physiol Neurobiol. 2013; 189: 241-249
        • Hagemans M.L.
        • Hop W.J.
        • Van Doorn P.A.
        • Reuser A.J.
        • Van der Ploeg A.T
        Course of disability and respiratory function in untreated late-onset Pompe disease.
        Neurology. 2006; 66: 581-583
        • Wenninger S.
        • Montagnese F.
        • Schoser B
        Core clinical phenotypes in myotonic dystrophies.
        Front Neurol. 2018; 9: 303
        • Fregonezi G.
        • Azevedo I.G.
        • Resqueti V.R.
        • et al.
        Muscle impairment in neuromuscular disease using an expiratory/inspiratory pressure ratio.
        Respir Care. 2015; 60: 533-539